

INDEX OF TABLES

Table 1: Pletal 100 mg Twice Daily. Impact on Walking Distance. Summary of Changes in Six randomized Trials	7.
Table 2: Europe Pletal Marketing History	7.
Table 3: United Kingdom and Germany Pletal Revenues	8.
Table 4: U.K. 2002-2007 YTD Annual Cost of Pletal Therapy	9.
Table 5: U.K. Annual Cost of Drug Therapy for Symptoms of Intermittent Claudication	9.
Table 6: Western Europe Region Total Revenues of Four Major Oral Intermittent Claudication Therapies	10.
Table 7: Western Europe Revenues by Chemical Entity Based on IMS Data for ICD-10 Code for Intermittent Claudication	11.
Table 8: Western Europe Intermittent Claudication Market Comparison Based on Revenues of Four Major Oral Intermittent Claudication Therapies with Revenues for ICD-10 Diagnosis Code for Intermittent Claudication	11.
Table 9: Western Europe Comparison of the 2006 Intermittent Claudication Revenues and Estimated Number of People with PAD and IC by Country	13.
Table 10: Germany 2000-2007 YTD Revenues of Major Oral Intermittent Claudication Therapies	14.
Table 11: Italy 2000-2007 YTD Revenues of Major Oral Intermittent Claudication Therapies	15.
Table 12: France 2000-2007 YTD Revenues of Major Oral Intermittent Claudication Therapies	15.
Table 13: United Kingdom 2000-2007 YTD Revenues of Major Oral Intermittent Claudication Therapies	16.
Table 14: Spain 2000-2007 YTD Revenues of Major Oral Intermittent Claudication Therapies	16.
Table 15: Scandinavia 2000-2007 YTD Revenues of Major Oral Intermittent Claudication Therapies	17.
Table 16: The Netherlands 2000-2007 YTD Revenues of Major Oral Intermittent Claudication Therapies	17.
Table 17: Greece 2000-2007 YTD Revenues of Major Oral Intermittent Claudication Therapies	18.

Table 18: Portugal 2000-2007 YTD Revenues of Major Oral Intermittent Claudication Therapies	18.
Table 19: Belgium 2000-2007 YTD Revenues of Major Oral Intermittent Claudication Therapies	19.
Table 20: Austria 2000-2007 YTD Revenues of Major Oral Intermittent Claudication Therapies	19.
Table 21: Switzerland 2000-2007 YTD Revenues of Major Oral Intermittent Claudication Therapies	20.
Table 22: European Medicines Evaluation Agency Intermittent Claudication Phase III Clinical Trial Requirements	20.
Table 23: 2007 Estimated Number of People with PAD and IC In Western Europe by Country	24.
Table 24: Germany Potential Market for Pharmaceutical Therapies Higher Prevalence of Intermittent Claudication	25.
Table 25: Germany Potential Market for Pharmaceutical Therapies Lower Prevalence of Intermittent Claudication	25.
Table 26: Italy Potential Market for Pharmaceutical Therapies Higher Prevalence of Intermittent Claudication	26.
Table 27: Italy Potential Market for Pharmaceutical Therapies Lower Prevalence of Intermittent Claudication	26.
Table 28: France Potential Market for Pharmaceutical Therapies Higher Prevalence of Intermittent Claudication	27.
Table 29: France Potential Market for Pharmaceutical Therapies Lower Prevalence of Intermittent Claudication	27.
Table 30: United Kingdom Potential Market for Pharmaceutical Therapies Higher Prevalence of Intermittent Claudication	28.
Table 31: United Kingdom Potential Market for Pharmaceutical Therapies Lower Prevalence of Intermittent Claudication	28.
Table 32: Spain Potential Market for Pharmaceutical Therapies Higher Prevalence of Intermittent Claudication	29.
Table 33: Spain Potential Market for Pharmaceutical Therapies Lower Prevalence of Intermittent Claudication	29.

Table 34: Scandinavia Potential Market for Pharmaceutical Therapies Higher Prevalence of Intermittent Claudication	30.
Table 35: Scandinavia Potential Market for Pharmaceutical Therapies Lower Prevalence of Intermittent Claudication	30.
Table 36: The Netherlands Potential Market for Pharmaceutical Therapies Higher Prevalence of Intermittent Claudication	31.
Table 37: The Netherlands Potential Market for Pharmaceutical Therapies Lower Prevalence of Intermittent Claudication	31.
Table 38: Greece Potential Market for Pharmaceutical Therapies Higher Prevalence of Intermittent Claudication	32.
Table 39: Greece Potential Market for Pharmaceutical Therapies Lower Prevalence of Intermittent Claudication	32.
Table 40: Portugal Potential Market for Pharmaceutical Therapies Higher Prevalence of Intermittent Claudication	33.
Table 41: Portugal Potential Market for Pharmaceutical Therapies Lower Prevalence of Intermittent Claudication	33.
Table 42: Belgium Potential Market for Pharmaceutical Therapies Higher Prevalence of Intermittent Claudication	34.
Table 43: Belgium Potential Market for Pharmaceutical Therapies Lower Prevalence of Intermittent Claudication	34.
Table 44: Austria Potential Market for Pharmaceutical Therapies Higher Prevalence of Intermittent Claudication	35.
Table 45: Austria Potential Market for Pharmaceutical Therapies Lower Prevalence of Intermittent Claudication	35.
Table 46: Switzerland Potential Market for Pharmaceutical Therapies Higher Prevalence of Intermittent Claudication	36.
Table 47: Switzerland Potential Market for Pharmaceutical Therapies Lower Prevalence of Intermittent Claudication	36.
Table 48: 2007 Estimated Number of People with PAD and IC In Eastern Europe by Country	37.
Table 49: Poland Potential Market for Pharmaceutical Therapies Higher Prevalence of Intermittent Claudication	38.

Table 50: Poland Potential Market for Pharmaceutical Therapies Lower Prevalence of Intermittent Claudication	38.
Table 51: Romania Potential Market for Pharmaceutical Therapies Higher Prevalence of Intermittent Claudication	39.
Table 52: Romania Potential Market for Pharmaceutical Therapies Lower Prevalence of Intermittent Claudication	39.
Table 53: 2007 and 2020 Comparison of the Number of People with PAD, IC and the Market for IC Drug Therapy In Western Europe, Eastern Europe and the United States	40.